Pembrolizumab could be considered a new standard of care for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma who have relapsed post– autologous stem cell transplant or are ineligible for transplant, according researchers commenting on new trial findings presented at the ASCO 2020. Results from the phase III KEYNOTE-204 trial released as part of ...
Pembrolizumab may be new standard of care in relapsed/refractory Hodgkin lymphoma
By Michael Woodhead
2 Jun 2020